The level of IGFBP-2 was increased and IGFBP-3 reduced in SSc-no ILD (p < 0.05 and p < 0.001, respectively) and SSc-ILD patients (p < 0.001 and p < 0.05, respectively) compared to HS. This evidence concerns the gene IGFBP3 and systemic sclerosis.